Last reviewed · How we verify
Vivag Plus
Vivag Plus is a combination of two medications that work together to lower blood sugar levels.
Vivag Plus is a combination of two medications that work together to lower blood sugar levels. Used for Type 2 diabetes.
At a glance
| Generic name | Vivag Plus |
|---|---|
| Sponsor | Zealand University Hospital |
| Drug class | Sulfonylurea and meglitinide combination |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
Vivag Plus contains a sulfonylurea and a meglitinide, which stimulate insulin release from the pancreas and increase insulin sensitivity in the body. This helps to lower blood sugar levels in people with type 2 diabetes.
Approved indications
- Type 2 diabetes
Common side effects
- Hypoglycemia
- Weight gain
- Nausea
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Vivag Plus CI brief — competitive landscape report
- Vivag Plus updates RSS · CI watch RSS
- Zealand University Hospital portfolio CI